This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2023 May;113(5):945-947.

doi: 10.1002/cpt.2880.

Biomarkers Come of Age in Clinical Pharmacology

Kathleen M Giacomini¹

Affiliations

PMID: 37069736
DOI: 10.1002/cpt.2880

Editorial

Biomarkers Come of Age in Clinical Pharmacology

Kathleen M Giacomini. Clin Pharmacol Ther. 2023 May.

. 2023 May;113(5):945-947.

doi: 10.1002/cpt.2880.

Author

Kathleen M Giacomini¹

Affiliation

¹ Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California, USA.

PMID: 37069736
DOI: 10.1002/cpt.2880

No abstract available

PubMed Disclaimer

Comment on

Biomarkers and surrogate endpoints: preferred definitions and conceptual framework.
Biomarkers Definitions Working Group.. Biomarkers Definitions Working Group.. Clin Pharmacol Ther. 2001 Mar;69(3):89-95. doi: 10.1067/mcp.2001.113989. Clin Pharmacol Ther. 2001. PMID: 11240971 Review. No abstract available.

Similar articles

[Clinical pharmacology and immunotherapy, 4th edition of the congress of pharmacology of anticancer drugs].
de Percin S, Fidelle M, Carton E, Goldwasser F. de Percin S, et al. Bull Cancer. 2017 Sep;104(9):807-811. doi: 10.1016/j.bulcan.2017.06.005. Epub 2017 Aug 4. Bull Cancer. 2017. PMID: 28784244 French. No abstract available.
Surrogate markers and clinical pharmacology.
Colburn WA. Colburn WA. J Clin Pharmacol. 1995 May;35(5):441-2. doi: 10.1002/j.1552-4604.1995.tb04086.x. J Clin Pharmacol. 1995. PMID: 7657842 No abstract available.
A Perspective on Quantitative Systems Pharmacology Applications to Clinical Drug Development.
Bai JPF, Earp JC, Strauss DG, Zhu H. Bai JPF, et al. CPT Pharmacometrics Syst Pharmacol. 2020 Dec;9(12):675-677. doi: 10.1002/psp4.12567. Epub 2020 Nov 7. CPT Pharmacometrics Syst Pharmacol. 2020. PMID: 33159491 Free PMC article. No abstract available.
The contribution of clinical pharmacology surrogates and models to drug development--a critical appraisal.
Rolan P. Rolan P. Br J Clin Pharmacol. 1997 Sep;44(3):219-25. doi: 10.1046/j.1365-2125.1997.t01-1-00583.x. Br J Clin Pharmacol. 1997. PMID: 9296315 Free PMC article. Review. No abstract available.
[Clinical pharmacology as translational research].
Ueda S. Ueda S. Nihon Yakurigaku Zasshi. 2010 Aug;136(2):107-10. doi: 10.1254/fpj.136.107. Nihon Yakurigaku Zasshi. 2010. PMID: 20702971 Review. Japanese. No abstract available.

See all similar articles

References

1. Biomarkers Definitions Working Group Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 69, 89-95 (2001).
1. Strimbu, K. & Tavel, J.A. What are biomarkers? Curr. Opin. HIV AIDS 5, 463-466 (2010).
1. https://www.fda.gov/drugs/biomarker-qualification-program/about-biomarke.... Accessed 22 February 2023
1. Rodrigues, A.D. Reimagining the framework supporting the static analysis of transporter drug interaction risk; integrated use of biomarkers to generate pan-transporter inhibition signatures. Clin. Pharmacol. Ther. 113, 986-1002 (2023).
1. Lin, J. et al. Effect of hepatic impairment on OATP1B activity: quantitative pharmacokinetic analysis of endogenous biomarker and substrate drugs. Clin. Pharmacol. Ther. 113, 1058-1069 (2023).

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Wiley